协同医疗遗传进化优化和深度卷积生成增强与SHAP驱动的可解释性,用于精确的阿尔茨海默病严重程度分级.
H C Bharath1, N Pradeep1, R Shashidhar2
1Bapuji Institute of Engineering and Technology, Davangere, Affiliated to Visvesvaraya Technological University, Belagavi, 590018, India.
Brain informatics
|November 26, 2025
概括
这项研究介绍了使用医学遗传算法 (MedGA) 优化的卷积神经网络 (CNN) 和深层卷积生成对抗网络 (DCGAN) 进行早期阿尔茨海默病诊断的先进框架. 该方法提高了诊断准确性和可解释性,这对于及时干预至关重要.
科学领域:
- 医学成像分析 医学成像分析
- 医疗保健中的人工智能
- 神经科学是一个神经科学.
背景情况:
- 准确的早期阿尔茨海默病 (AD) 诊断对于有效的治疗至关重要,但由于数据不平衡,模型可解释性和计算成本而受到阻碍.
- 现有的诊断模型经常与不平衡的数据集和缺乏透明度扎,影响临床采用.
研究的目的:
- 开发一个新的,端到端的诊断框架,用于早期和准确的阿尔茨海默病检测.
- 为了应对数据不平衡,模型解释性低,AD诊断中的计算成本高的挑战.
主要方法:
- 利用医学遗传算法 (MedGA) 优化的卷积神经网络 (CNN) 与深层卷积生成对抗网络 (DCGAN) 集成,用于合成MRI生成.
- 为了模型的可解释性,采用了SHapley添加式扩展 (SHAP),分析了像海马体和杏仁体这样的关键大脑区域.
- 培训并验证了Open Access系列成像研究 (OASIS) 数据集的框架,重点关注四个AD阶段.
主要成果:
- DCGAN生成了700个合成MRI,将回忆能力提高了10%,并平衡了中度痴呆症类数据集 (SSIM=0.92).
- MedGA优化了CNN的超参数,将网络复杂度降低了20%,同时保持了97%的测试准确度.
- SHAP分析显示,海马和杏仁核对分类至关重要,提高了25%的解释性和临床医生的信心.
结论:
- 与阿尔茨海默病诊断的最先进方法相比,拟议的框架显示出优越的预测性能和可解释性.
- 这种综合方法为早期AD分类提供了强大的工具,有望提高医疗保健机构的诊断精度.
关键词:
阿尔茨海默氏症 (AD) 是一种疾病.卷积神经网络 (CNN) 是一种神经网络.深度卷积生成对抗网络 (DCGAN) 是一个深度卷积生成对抗网络.医学遗传算法 (MedGA) 是一种医学遗传算法.SHAP (夏普利添加式解释) 和增强.更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.5K
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.3K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
